Expert Opinion on Biological Therapy

Article	Citations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	63
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	59
Biosimilars and access to biologic therapy in immune-mediated diseases	55
The endosomal-lysosomal system in ADC design and cancer therapy	53
IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?	40
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	38
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions	35
Antibody drug conjugates for glioblastoma: current progress towards clinical use	35
Aflibercept biosimilars – so near, yet so far	32
Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab	31
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	30
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas	29
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	29
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	29
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials	27
Correction	27
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	27
Signaling new therapeutic opportunities: cytokines in prostate cancer	26
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	25
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	23
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	22
Long-acting delivery and therapies for neovascular age-related macular degeneration	22
TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort	21
Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies	21
Temporal mismatch in allogeneic iPSC therapies: biological risks and implications for clinical translation	21

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering—an expert perspective	21
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	21
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies	20
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	20
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis	20
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases	20
Cell population data as predictive biomarkers for biologic therapy response in psoriasis	20
New biological agents in systemic lupus erythematosus	19
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	19
Correction	19
Unmet needs in cervical cancer – can biological therapies plug the gap?	19
An evaluation of guselkumab for the treatment of ulcerative colitis	18
Correction	18
ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer	17
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	17
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	17
Relapses in giant cell arteritis: challenges after discontinuation of targeted therapies	17
Dynamics of biological markets with multiple biosimilar competitors in the United States	16
Beyond innovation: why rare disease gene therapy needs a reset	16
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	16
Strategies for extending the half-life of biotherapeutics: successes and complications	16
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?	15
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	15
The nail in psoriatic arthritis: new insights into prognosis and treatment	15
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	15
Emerging strategies for the prevention and management of chronic graft-versus-host disease	15
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	14
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	14
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	14
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	14
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	14
Management of proctitis in ulcerative colitis and the place of biological therapies	14
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	13
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	13
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	13
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials	13
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	13
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	13
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	13
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	13
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	12
Emerging peptide-based technology for biofilm control	12
Personalizing immunotherapy for renal cell carcinoma: how far have we come?	12
Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer	12
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients	12
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	12
Tarlatamab for small-cell lung cancer	12
Recent developments and future clinical prospects of polyclonal antibody therapies	11
An evaluation of pozelimab for the treatment of CHAPLE disease	11
Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression	11

Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	11
Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence	11
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	11
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	11
Correction	11
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	11
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects	11
Tremelimumab for the treatment of hepatocellular carcinoma	11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	11
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	10
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	10
Belimumab patient profile in Spain: evolution during the last decade and future directions	10
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	10
Clinical management and innovation in fracture non-union	10
Non-traditional approaches for control of antibiotic resistance	10
The role of monoclonal antibodies in the treatment of lupus nephritis	10
Biosimilars in osteoporosis treatment: focus on denosumab	10
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	10
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	9
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	9
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	9
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	9
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics	9
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence	9
Correction	8
Antibody therapeutics for epithelial ovarian cancer	8
Breaking immune exclusion in cold tumors via TGF-β pathway inhibition	8
Epcoritamab in B-cell malignancies: current status and prospects	8
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	8
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	8
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	8
X-linked myotubular myopathy: an untreated treatable disease	8
Comparative overview of biosimilar regulatory frameworks and international harmonization trends	8
Current status and future potential of CD123-based targeted therapies for acute leukemia	8
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	8
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectives	8
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	8
Sargramostim in acute radiation syndrome	8
Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial	8
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	8
Biologics in rectal cancer	8
The future of interleukin gene therapy in head and neck cancers	7
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	7
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study	7
The future of cellular therapy for the treatment of renal cell carcinoma	7
Belantamab mafodotin in multiple myeloma	7
CAR T cells for solid tumors – developments to watch in 2023	7
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	7
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	7
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	7
Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis	7
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	7
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	7
Monoclonal antibodies in the management of hereditary angioedema	7
Biologic therapy through caregivers’ eyes: insights from a multicenter pediatric rheumatology survey	7
Advances in the management of giant cell arteritis–aortitis: biologic therapies and beyond - a narrative review	7
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	7
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective	7
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	7
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis	7
Improving health literacy and patient-directed knowledge of fecal microbiota transplantation (FMT) through analysis of readability: a cross-sectional infodemiology study	7
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	7
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	7
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	7
Expression of Concern:	7
Ravulizumab for the treatment of myasthenia gravis	7
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	7
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations	6
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?	6
Treatment options for advanced hepatocellular carcinoma: the potential of biologics	6
Targeting ineffective erythropoiesis in thalassemia: biologic therapies and emerging therapeutic strategies	6
Gene therapy for choroideremia: progress, potential and pitfalls	6
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma	6
Non-TNF biologics and their biosimilars in rheumatoid arthritis	6
Targeting two pathways at once: the emerging role of bispecific antibodies in NSCLC and SCLC	6
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars	6
The future of aptamers in cancer diagnosis, prognosis and treatment	6
Real-world effectiveness and predictors of complete skin clearance (PASI 100) with anti-IL-23 monoclonal antibodies in moderate-to-severe psoriasis: a retrospective cohort study	6

Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives	6
Gene therapy approaches for inborn errors of immunity: from bench to bedside	6
Extracellular RNAs in pancreatic cancer: from pathogenesis to precision medicine	6
Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China	6
The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?	6
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm	6
The future of cancer vaccines against colorectal cancer	6
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis	6
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies	6
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?	6
Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery	6
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting	6
Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection	6
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder	6
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence	6
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas	5
Correction	5
Elotuzumab in multiple myeloma	5
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach	5
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience	5
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges	5
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma	5
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients	5
Biological drugs for the treatment of children with atopic dermatitis	5
Hypoxic storage of red blood cells to improve transfusion outcomes in hematological malignancies	5
Could siRNA therapeutics change the way we treat dyslipidemia?	5
Current and preclinical treatment options for Merkel cell carcinoma	5
Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis	5
Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience	5
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?	5
Bintrafusp alfa and its unsuccessful development journey towards cervical cancer treatment	5
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial	5
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey	5
Perceptions of airway gene therapy for cystic fibrosis	5
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel	5
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma	5
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer	5
What does the future hold for antibody-drug conjugate therapies in ovarian cancer?	5
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma	5
Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?	4
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chron	4
How treatment choices influence the onset and outcomes of uveitis in juvenile idiopathic arthritis: a retrospective cohort study	4
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?	4
Biosimilar stewardship at the interface of disproportionality methods and AI integration: current evidence and potential strategies	4
Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States	4
Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch	4
Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review	4
Next-generation CAR-NK cell therapy for glioblastoma: strategies to overcome antigen escape and the immunosuppressive tumor microenvironment	4
An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions	4
Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics	4
Addressing practical challenges with bispecific antibody therapy in multiple myeloma	4
Optimizing the use of vilobelimab for the treatment of COVID-19	4
Biologics for dengue prevention: up-to-date	4
A situational analysis of the adoption of oncology, inflammation, and supportive care biosimilars in the United States	4
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center	4
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy	4
An evaluation of nipocalimab for the treatment of generalized myasthenia gravis	4
Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease	4
Short and long-term economic implications of biosimilars	4
Targeting cervical cancer with anti-PD-1 antibodies: what is new?	4
Clinical advances in biological therapy for generalized pustular psoriasis: a review	4
Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis	4
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement	4
Emerging anti-spike monoclonal antibodies against SARS-CoV-2	4
The evolving therapeutic landscape of diabetic retinopathy	4
Oncolytic virus therapy for malignant gliomas: entering the new era	4
An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer	4
Recent developments in CD19-targeted therapies for follicular lymphoma	4
Sarilumab in the treatment of rheumatoid arthritis: future perspectives	4
Correction	4
Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects	4
Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance	4
Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian VALORE distributed database network	4
Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors	4
Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis	4
Targeting autoimmune pulmonary alveolar proteinosis with GM-CSF: insights from clinical trials and emerging therapies	4
Perispinal etanercept stroke trial design: PESTO and beyond	4
Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps	3
Switching CGRP(r) MoAbs in migraine: what evidence?	3
Clinical use of biologics in juvenile idiopathic arthritis: lessons learned from real-world studies	3
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 st	3
The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents	3
A plain language summary of the pooled safety results of adalimumab-adbm from the VOLTAIRE clinical trials in people with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	3
Developing combination therapies with biologics in triple-negative breast cancer	3
Biologics for psoriasis: is there any unmet need left?	3
Adjuvant immunotherapy for locally advanced renal cell carcinoma	3
Clinical use of intravenous immunoglobulin in juvenile dermatomyositis: indications, treatment course, and clinical outcomes	3
Small molecule-regulated switches to provide functional control of CAR T cells within the patient	3
What role can LAG-3-blocking antibodies play in melanoma therapy?	3
What is ‘ chronic ’ pustular psoriasis? Identifying candidates for long-term subcutaneous spesolimab treatment	3
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity	3
Management of metastatic melanoma with combinations including PD-1 inhibitors	3
Biological therapies for the treatment of psoriasis in pediatrics	3
Biological therapies in thrombocytopenia and primary antiphospholipid syndrome: where are we now?	3
Reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence	3